Revision history of "P42-TAT" (Q3679804)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

11 October 2024

  • curprev 11:2711:27, 11 October 2024DG Regio talk contribs 54,042 bytes −12 Set a claim value: summary (P836): O objetivo do projeto P42-TAT é avaliar o potencial pré-clínico de um péptido de 36 aminoácidos (P42-TAT) protetor contra a doença de Huntington. A doença de Huntington é uma doença neurodegenerativa rara devido à expansão do domínio poliQ da proteína huntingtina (HTT). Será liderado por uma equipa de investigação liderada por Florence Maschat no laboratório MMDN (Moldecular Mechanisms in Neurodegenerative Demences; Inserm 1198) localizado na Univer...

7 March 2024

12 January 2024

19 June 2023

11 June 2023

8 June 2023

11 August 2022

  • curprev 16:1316:13, 11 August 2022DG Regio talk contribs 50,794 bytes +34,266 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

14 January 2022

13 January 2022

6 December 2021

1 December 2021

  • curprev 08:0808:08, 1 December 2021DG Regio talk contribs 11,093 bytes +1,732 Created claim: summary (P836): Ziel des Projekts P42-TAT ist es, das präklinische Potenzial eines 36-Aminosäure-Peptids (P42-TAT) zu bewerten, das vor der Huntington-Krankheit geschützt ist. Die Huntington-Krankheit ist eine seltene neurodegenerative Erkrankung, die auf die Erweiterung des PolyQ-Bereichs des Huntingtin-Proteins (HTT) zurückzuführen ist. Es wird von einem Forschungsteam unter der Leitung von Frau Florence Maschat im Labor MMDN (Molekulare Mechanismen in neur...

27 November 2021

  • curprev 12:2512:25, 27 November 2021DG Regio talk contribs 9,361 bytes −1,737 Removed claim: summary (P836): Le projet P42-TAT a pour but d‚évaluer le potentiel préclinique d‘un peptide de 36 acides Aminés (P42-TAT) protecteur contre la maladie de Huntington. La maladie de Huntington est une maladie neurodégénérative rare due à l’expansion du domaine polyQ de la protéine hunttine (Htt). Il sera mené par une équipe de recherche dirigée par Madame Florence Maschat au sein du laboratoire MMDN (mécanismes moléculaires dans les Démences Neurodégénérativ...

26 November 2021

  • curprev 23:1723:17, 26 November 2021DG Regio talk contribs 11,098 bytes +1,737 Created claim: summary (P836): Le projet P42-TAT a pour but d‚évaluer le potentiel préclinique d‘un peptide de 36 acides Aminés (P42-TAT) protecteur contre la maladie de Huntington. La maladie de Huntington est une maladie neurodégénérative rare due à l’expansion du domaine polyQ de la protéine hunttine (Htt). Il sera mené par une équipe de recherche dirigée par Madame Florence Maschat au sein du laboratoire MMDN (mécanismes moléculaires dans les Démences Neurodégénératives...
  • curprev 14:5014:50, 26 November 2021DG Regio talk contribs 9,361 bytes +67 Changed label, description and/or aliases in de: translated_label

24 November 2021

18 November 2021

  • curprev 16:4416:44, 18 November 2021DG Regio talk contribs 8,863 bytes +65 Changed label, description and/or aliases in en: translated_label
  • curprev 16:4416:44, 18 November 2021DG Regio talk contribs 8,798 bytes +1,637 Created claim: summary (P836): The aim of the P42-TAT project is to assess the preclinical potential of a 36 amino acid peptide (P42-TAT) protective against Huntington’s disease. Huntington’s disease is a rare neurodegenerative disease due to the expansion of the polyQ domain of huntingtin protein (HTT). It will be led by a research team led by Ms Florence Maschat within the MMDN laboratory (Moldecular Mechanisms in Neurodegenerative Demences; Inserm 1198) located at the Un...

17 November 2021